![]() ![]() | Faville, C.* , E Silva, B.* , Jassin, M., DUBOIS, S., Daulne, C., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M.* , & Ehx, G.*. (06 February 2024). Discovery And Targeting of Persister-specific Antigens in Acute Myeloid Leukemia [Poster presentation]. Télévie Seminar. * These authors have contributed equally to this work. |
![]() ![]() | Faville, C.* , E Silva, B.* , Jassin, M., DUBOIS, S., Daulne, C., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M.* , & Ehx, G.*. (06 February 2024). Discovery And Targeting of Persister-specific Antigens in Acute Myeloid Leukemia [Paper presentation]. Télévie Seminar. * These authors have contributed equally to this work. |
![]() ![]() | Beguin, C., Kwan, O., Ritacco, C., Debray, J.-C., Dejardin, E., Dubois, S., Köse, M. C., Canti, L., Courtois, J., Seidel, L., Daulne, C., Caers, J., Beguin, Y., Ehx, G., & Baron, F. (17 November 2023). TNF-α priming of human regulatory T cells does not increase their ability to prevent xenogeneic graft-versus-host disease [Paper presentation]. Congrès annuel de la Société Francophone de Greffe de Moelle et Thérapie Cellulaire, Lille, France. ![]() |
![]() ![]() | E Silva, B., Faville, C., Jassin, M., DUBOIS, S., De Voeght, A., Baron, F., & Ehx, G. (09 September 2023). Characterizing the immune recognition of chemo-persister blasts in acute myeloid leukemia [Poster presentation]. GIGA Day 2023. |
![]() ![]() | Ritacco, C., Köse, M. C., Courtois, J., Canti, L., Beguin, C., DUBOIS, S., Vandenhove, B., Servais, S., Caers, J., Beguin, Y., Ehx, G.* , & Baron, F.*. (17 March 2023). Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. iScience, 26 (3), 106085. doi:10.1016/j.isci.2023.106085 ![]() * These authors have contributed equally to this work. |
![]() ![]() | Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1 ![]() |
![]() ![]() | Ehx, G.* , Ritacco, C.* , HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505 ![]() * These authors have contributed equally to this work. |
![]() ![]() | Ritacco, C., Ehx, G., Canti, L., DUBOIS, S., Vandenhove, B., SERVAIS, S., Beguin, Y., & Baron, F. (01 March 2020). Ptcy Prevents Xenogeneic Gvhd without Abrogating Gvl Effects. Biology of Blood and Marrow Transplantation, 26 (3), 168. doi:10.1016/j.bbmt.2019.12.028 ![]() |
![]() ![]() | Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007 ![]() |
![]() ![]() | Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619 ![]() |
![]() ![]() | Muller, J., Duray, E., Lejeune, M., DUBOIS, S., Plougonven, E., Léonard, A., Storti, P., Giuliani, N., Cohen-Solal, M., Hempel, U., Thijssen, V., BEGUIN, Y., Heusschen, R., & CAERS, J. (2019). Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts. Cancers, 11 (2), 261. doi:10.3390/cancers11020261 ![]() |
![]() ![]() | Muller, J., Bolomsky, A., Dubois, S., Duray, E., Stangelberger, K., Plougonven, E., Lejeune, M., Léonard, A., Marty, C., Hempel, U., Baron, F., BEGUIN, Y., Cohen-Solal, M., Ludwig, H., Heusschen, R., & CAERS, J. (2018). Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. Haematologica, 103, 1359-1368. doi:10.3324/haematol.2017.185397 ![]() |
Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease [Poster presentation]. 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium. |
Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., Beguin, Y., & Baron, F. (27 March 2017). Xenogeneic graft-versus-host disease : Impact of Th17 cells [Poster presentation]. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France. |
![]() ![]() | Ehx, G., Hannon, M., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (March 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Biology of Blood and Marrow Transplantation, 23 (3), 365–S366. doi:10.1016/j.bbmt.2016.12.314 ![]() |
Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (February 2017). Impact of Th17 population on xenogeneic graft-versus-host disease [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium. |
![]() ![]() | Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425 ![]() |
![]() ![]() | Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria. |
Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (08 December 2016). Xenogeneic graft-versus-host disease: Impact of Th17 cells [Poster presentation]. Journée des chercheurs Télévie 2017, Bruxelles, Belgium. |
Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique [Paper presentation]. 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium. |
Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (18 November 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. Congrès Commun de la SFGM-TC et de la SFBCT, Liège, Belgium. ![]() |
![]() ![]() | Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2 ![]() * These authors have contributed equally to this work. |
Delens, L., BEGUIN, Y., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., SERVAIS, S., & BARON, F. (27 May 2016). Th17 cell population seems to aggravate xenogeneic graft-versus-host disease [Poster presentation]. 2016 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium. |
![]() ![]() | Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (March 2016). Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 22 (3), 393. doi:10.1016/j.bbmt.2015.11.917 ![]() |
Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium. |
Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (29 January 2016). Salt but not glucocorticoïds enhances Th17 differentiation from naïve T cells in vitro [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium. |
![]() ![]() | Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society. |
Ehx, G., Hannon, M., Humblet-Baron, S., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., & BARON, F. (29 January 2016). Immunomodulatory effects of rapamycin in Graft versus Host Disease [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium. |
![]() ![]() | Fransolet, G., Ehx, G., SOMJA, J., Delens, L., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., DELVENNE, P., BEGUIN, Y., Conteduca, G., & Baron, F. (29 January 2016). Azacytidine and Decitabine prevent experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 31st general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium. |
![]() ![]() | Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy. |
![]() ![]() | Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750 ![]() * These authors have contributed equally to this work. |
![]() ![]() | Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology. ![]() |
Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium. |
Delens, L., Servais, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Daulne, C., Vrancken, L., Beguin, Y., & Baron, F. (03 December 2015). Revisiting Th17 cell subsets in the setting of allogeneic stem cell transplantation and (cortico-refractory) graft-versus-host disease [Poster presentation]. Journée Télévie 2016, Gembloux, Belgium. |
![]() ![]() | Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale [Paper presentation]. 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France. |
Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (13 November 2015). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. EORTC Leukemia Group-GIMEMA meeting, Rome, Italy. ![]() |
Delens, L., SERVAIS, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Beguin, Y., & Baron, F. (30 January 2015). Effects of Tocilizumab on Th17 cell differentiation in a humanized mouse model of xenogeneic graft-versus-host disease [Poster presentation]. 30st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium. |
![]() ![]() | Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book. ![]() |
![]() ![]() | Ehx, G., HANNON, M., DUBOIS, S., HALLEUX, A., Belle, L., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (27 January 2014). Immunomodulatory effects of Rapamycin in xenogeneic GVHD [Poster presentation]. GIGA Day 2014, Liège, Belgium. |
![]() ![]() | Fransolet, G., Belle, L., SOMJA, J., Humblet-Baron, S., DUBOIS, S., Delvenne, P., Beguin, Y., & Baron, F. (January 2014). Imatinib improves survival of chronic Graft-versus-host disease by inhibiting TGF-β and PDGF-R in mice [Poster presentation]. 29th general annual meeting of the Belgian Hematological Society, Ghent, Belgium. |
![]() ![]() | Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003 ![]() * These authors have contributed equally to this work. |
![]() ![]() | Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317. ![]() |
![]() ![]() | Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41. |
![]() ![]() | Menten, C., Faccinetto, C., Golovchenko, M., Dupiereux-Fettweis, I., Van Lerberghe, P.-B., DUBOIS, S., Desmet, C., Elmoualij, B., Baron, F., Rudenko, N., Oury, C., Heinen, E., & Couvreur, B. (December 2012). Neutrophil Extracellular Traps (NET) Entrap and Kill Borrelia burgdorferi sensu stricto Spirochetes and Are not Affected by Ixodes ricinus Tick Saliva. Journal of Immunology, 189 (11), 5393-5401. doi:10.4049/jimmunol.1103771 ![]() |
![]() ![]() | Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting. |
![]() ![]() | Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society. |
![]() ![]() | Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16. |
![]() ![]() | Bruck, F., Baron, F., DUBOIS, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., Beguin, Y., & Humblet-Baron, S. (February 2011). Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells [Poster presentation]. ASBMT meeting 2011. doi:10.1016/j.bbmt.2010.12.535 |
![]() ![]() | Briquet, A., Dubois, S., Bekaert, S., Dolhet, M., Beguin, Y., & Gothot, A. (2010). Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID -repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica, 95 (1), 47-56. doi:10.3324/haematol.2009.008524 ![]() |